Diagnosing the decline in pharmaceutical R&D efficiency
The DOI matches its Crossref record; 85 of the 85 references it cites were found in a registry or an index.
Abstract
The past 60 years have seen huge advances in many of the scientific, technological and managerial factors that should tend to raise the efficiency of commercial drug research and development (RD). Yet the number of new drugs approved per billion US dollars spent on RD has halved roughly every 9 years since 1950, falling around 80-fold in inflation-adjusted terms. There have been many proposed solutions to the problem of declining RD efficiency. However, their apparent lack of impact so far and the contrast between improving inputs and declining output in terms of the number of new drugs make it sensible to ask whether the underlying problems have been correctly diagnosed. Here, we discuss four factors that we consider to be primary causes, which we call the 'better than the Beatles' problem; the 'cautious regulator' problem; the 'throw money at it' tendency; and the 'basic research-brute force' bias. Our aim is to provoke a more systematic analysis of the causes of the decline in RD efficiency.
Overview
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
In the citing paper
“For over fifty years, the pharmaceutical industry has seen the cost of developing drugs increase exponentially from tens of millions in the 1950s to billions of dollars today, even when the data is adjusted for inflation [1].”
From Drug design on quantum computers (2024) · doi:10.1038/s41567-024-02411-5 · cites this paper as [1]
Citations
Cites
Collective dynamics of ‘small-world’ networks
Watts, D. J., & Strogatz, S. H. (1998) · Nature · doi:10.1038/30918 · Cited by 43,060
Lipinski, C. A., Lombardo, F., Dominy, B. W., & Feeney, P. J. (2001) · Advanced Drug Delivery Reviews · doi:10.1016/s0169-409x(00)00129-0 · Cited by 18,139
OLSSON, A. G., McMurray, J. J. V., Thorgeirsson, G., Spaulding, C. M., Slattery, J., Pyörälà, K., Færgeman, O., Wright, R. S., Berg, K. M., Wilhelmsen, L., et al. (1994) · The Lancet · Cited by 8,467
Improved survival with vemurafenib in melanoma with BRAF V600E mutation
Chapman, P. B., Hauschild, A., Robert, C., Haanen, J. B., Ascierto, P., Larkin, J., Dummer, R., Garbe, C., Testori, A., Maio, M., et al. (2011) · New England Journal of Medicine · doi:10.1056/nejmoa1103782 · Cited by 7,720
Identification of the transforming EML4–ALK fusion gene in non-small-cell lung cancer
Soda, M., Choi, Y. L., Enomoto, M., Takada, S., Yamashita, Y., Ishikawa, S., Fujiwara, S.-I., Watanabe, H., Kurashina, K., Hatanaka, H., et al. (2007) · Nature · doi:10.1038/nature05945 · Cited by 5,439 · cited 1×
“It is hard to look at the genesis of drugs like crizotini”
BackgroundCan the pharmaceutical industry reduce attrition rates?
Kola, I., & Landis, J. (2004) · Nature Reviews Drug Discovery · doi:10.1038/nrd1470 · Cited by 4,167
SCANDINAVIANSIMVASTATINSURVIVAL (1994) · The Lancet · doi:10.1016/s0140-6736(94)90566-5 · Cited by 3,645
How to improve R&D productivity: the pharmaceutical industry's grand challenge
Paul, S. M., Mytelka, D. S., Dunwiddie, C. T., Persinger, C. C., Munos, B. H., Lindborg, S. R., & Schacht, A. L. (2010) · Nature Reviews Drug Discovery · doi:10.1038/nrd3078 · Cited by 3,566
How many drug targets are there?
Overington, J. P., Al-Lazikani, B., & Hopkins, A. L. (2006) · Nature Reviews Drug Discovery · doi:10.1038/nrd2199 · Cited by 3,505
Hopkins, A. L., & Groom, C. R. (2002) · Nature Reviews Drug Discovery · doi:10.1038/nrd892 · Cited by 3,305 · cited 1×
“First, estimates of the number of potential drug target”
Background
Research works printed but not linked: 6
- Ruffolo, R. R. Engineering success: Wyeth redefines its research & development organisation. Drug Discovery World website [online] , (2005).
- Young, M. P. Prediction v Attrition. Drug Discovery World website [online] , (2008).
- Healy, D. The Psychopharmacologists: Volume 2 93–118 (Hodder Arnold, London, 1999).
- Healy, D. The Psychopharmacologists: Volume 2 259–264 (Hodder Arnold, London, 1999).
- Mathieu, M. P. (ed.) Parexel's Bio/Pharmaceutical R&D Statistical Sourcebook 2010/2011 163–261 (Barnett International, Needham, Massachusetts, 2010).
- Munos, B. How to avert biopharma's R&D crisis. In Vivo 29, 2011800050 (2011).
Cited by
Items 201–300 of 1,002
Old wine in new bottles: Drug repurposing in oncology
Antoszczak, M., Markowska, A., Markowska, J., & Huczyński, A. (2019) · European Journal of Pharmacology · doi:10.1016/j.ejphar.2019.172784 · Cited by 94
3d organ-on-a-chip: the convergence of microphysiological systems and organoids
Baptista, L. S., Porrini, C., Kronemberger, G. S., Kelly, D. J., & Perrault, C. M. (2022) · Frontiers in Cell and Developmental Biology · doi:10.3389/fcell.2022.1043117 · Cited by 90
“To reach approval, the novel drug must show safety and effectiveness in humans (Scannell et al., 2012).”
BackgroundJiang, X., Lü, W., Shen, X., Wang, Q., Lv, J., Liu, M., Cheng, F., Zhao, Z., & Pang, X. (2018) · JCI Insight · doi:10.1172/jci.insight.98921 · Cited by 94
High-throughput approaches for precision medicine in high-grade serous ovarian cancer
Govindarajan, M., Wohlmuth, C., Waas, M., Bernardini, M. Q., & Kislinger, T. (2020) · Journal of Hematology & Oncology · doi:10.1186/s13045-020-00971-6 · Cited by 96
Mazzucato, M., & Parris, S. (2014) · Small Business Economics · doi:10.1007/s11187-014-9583-3 · Cited by 89
“2010), and firms have struggled to produce blockbuster products, resulting in a rising cost for each new molecular entity (NME) approved (Scannell et al. 2012).”
BackgroundIn silico structure-based approaches to discover protein-protein interaction-targeting drugs
Shin, W., Christoffer, C. W., & Kihara, D. (2017) · Methods · doi:10.1016/j.ymeth.2017.08.006 · Cited by 91
Inventing new therapies without reinventing the wheel: the power of drug repurposing
Papapetropoulos, A., & Szabó, C. (2018) · British Journal of Pharmacology · doi:10.1111/bph.14081 · Cited by 91
An integrative machine learning approach for prediction of toxicity-related drug safety
Lysenko, A., Sharma, A., Boroevich, K. A., & Tsunoda, T. (2018) · Life Science Alliance · doi:10.26508/lsa.201800098 · Cited by 88
Cheng, F., Hong, H., Yang, S., & Wei, Y. (2016) · Briefings in Bioinformatics · doi:10.1093/bib/bbw051 · Cited by 99
Targeting the schizophrenia genome: a fast track strategy from GWAS to clinic
Lencz, T., & Malhotra, A. K. (2015) · Molecular Psychiatry · doi:10.1038/mp.2015.28 · Cited by 94
Gittelman, M. (2016) · Research Policy · doi:10.1016/j.respol.2016.01.007 · Cited by 87
Mahalmani, V., Sinha, S., Prakash, A., & Medhi, B. (2022) · Indian Journal of Pharmacology · doi:10.4103/ijp.ijp_860_22 · Cited by 87
“[15,16] With drug repurposing, drugs can be developed in a shorter span within 4–5 years with less risk of failure and at a lower cost, as such drugs will have already gone through the early stages of drug development. environments.”
Human Genetics of Obesity and Type 2 Diabetes Mellitus: Past, Present, and Future
Ingelsson, E., & McCarthy, M. I. (2018) · Circulation Genomic and Precision Medicine · doi:10.1161/circgen.118.002090 · Cited by 95
Cone Snail Venomics: From Novel Biology to Novel Therapeutics
Prashanth, J. R., Brust, A., Jin, A., Alewood, P. F., Dutertre, S., & Lewis, R. J. (2014) · Future Medicinal Chemistry · doi:10.4155/fmc.14.99 · Cited by 90
Langley, G. R., Adcock, I. M., Busquet, F., Crofton, K. M., Csernok, E., Giese, C., Heinonen, T., Herrmann, K., Hofmann-Apitius, M., Landesmann, B., et al. (2017) · Drug Discovery Today · doi:10.1016/j.drudis.2016.10.011 · Cited by 84
Bojadzic, D., & Buchwald, P. (2018) · Current Topics in Medicinal Chemistry · doi:10.2174/1568026618666180531092503 · Cited by 86
“There are multiple possible reasons for this decrease in drug discovery and development efficiency, including an increasing regulatory burden, an unrealistic public expectation of no side effects, and many others [5, 8, 9]; here, we will highlight briefly the depletion of effective new targets for traditional drug des…”
BackgroundWhy and how have drug discovery strategies in pharma changed? What are the new mindsets?
Mignani, S. M., Huber, S., Tomás, H., Rodrigues, J., & Majoral, J. (2015) · Drug Discovery Today · doi:10.1016/j.drudis.2015.09.007 · Cited by 99
Drug Repositioning Approaches for the Discovery of New Therapeutics for Alzheimer's Disease
Kim, T. (2014) · Neurotherapeutics · doi:10.1007/s13311-014-0325-7 · Cited by 87
“, medical and financial benefits resulting from the drug), dramatically deceased and, at the time of writing, remains low [1–3].”
BackgroundEvolution of commercially available compounds for HTS
Volochnyuk, D. M., Ryabukhin, S. V., Moroz, Y. S., Savych, O., Chuprina, A., Horvath, D., Zabolotna, Y., Varnek, A. A., & Judd, D. B. (2018) · Drug Discovery Today · doi:10.1016/j.drudis.2018.10.016 · Cited by 84
Drug targets for COVID-19 therapeutics: Ongoing global efforts
Saxena, A. (2020) · Journal of Biosciences · doi:10.1007/s12038-020-00067-w · Cited by 89
“Some researchers and institutions also term ‘Drug repurposing’ as Drug Repositioning, Drug re-profiling or Drug re-tasking depending on the final outcome of studies (Scannell et al. 2012).”
BackgroundUse of artificial intelligence to enhance phenotypic drug discovery
Malandraki-Miller, S., & Riley, P. R. (2021) · Drug Discovery Today · doi:10.1016/j.drudis.2021.01.013 · Cited by 97
Ossai, J., Khatabi, B., Nybo, S. E., & Kharel, M. K. (2021) · Journal of Applied Microbiology · doi:10.1111/jam.15225 · Cited by 84
“The success of small molecule- based drug discovery and development relies on a variety of factors including the number of leads, the uniqueness in both structures and interactions with the target, physicochemical properties and the reliability of the production system (Scannell et al., 2012).”
BackgroundAntileishmanial Drug Discovery and Development: Time to Reset the Model?
Olías-Molero, A. I., de la Fuente, C., Cuquerella, M., Torrado, J. J., & Alunda, J. M. (2021) · Microorganisms · doi:10.3390/microorganisms9122500 · Cited by 93
“Some of them are (a) exhaustion of the so considered relatively easy achievable drugs (“low hanging fruits”) of less complex chemical synthesis and the help, in the first steps of chemotherapy, of the cumulative knowledge from traditional herbal medicine; (b) higher stringency of present requirements by regulatory age…”
BackgroundCoppens, M., Eikelboom, J. W., Gustafsson, D., Weitz, J. I., & Hirsh, J. (2012) · Circulation Research · doi:10.1161/circresaha.112.264903 · Cited by 83
A decade of innovation in pharmaceutical R&D: the Chorus model
Owens, P. K., Raddad, E., Miller, J. W., Stille, J. R., Olovich, K. G., Smith, N. V., Jones, R. S., & Scherer, J. C. (2014) · Nature Reviews Drug Discovery · doi:10.1038/nrd4497 · Cited by 90
US Pharma's Financialized Business ModelPreprint
Lazonick, W. H., Hopkins, M., Jacobson, K., Sakinç, M. E., & Tulum, Ö. (2017) · SSRN Electronic Journal · doi:10.2139/ssrn.3035529 · Cited by 102
“drugs to the plucking of “the low-hanging fruit” of decades of NIH-funded research (Nightingale and Martin 2004; Munos 2006; Scannell et al. 2012).”
BackgroundFunctionality‐Independent DNA Encoding of Complex Natural Products
Ma, P., Xu, H., Li, J., Lu, F., Ma, F., Wang, S., Xiong, H., Wang, W., Buratto, D., Zonta, F., et al. (2019) · Angewandte Chemie International Edition · doi:10.1002/anie.201901485 · Cited by 83
Executable cancer models: successes and challenges
Clarke, M. A., & Fisher, J. (2020) · Nature reviews. Cancer · doi:10.1038/s41568-020-0258-x · Cited by 88
“This can save time and expense by guiding experiments to those areas most likely to be effective and thereby overcome the slowdown in drug discovery currently attributed to the exhaustive nature of purely experimental approaches 11,12 .”
BackgroundIn silico drug combination discovery for personalized cancer therapy
Jeon, M., Kim, S., Park, S., Lee, H., & Kang, J. (2018) · BMC Systems Biology · doi:10.1186/s12918-018-0546-1 · Cited by 81
“However, the discovery and approval of new molecular entities has been on the decline in the pharmaceutical industry [1].”
BackgroundRodenhizer, D., Dean, T., D'Arcangelo, E., & McGuigan, A. P. (2018) · Advanced Healthcare Materials · doi:10.1002/adhm.201701174 · Cited by 80
Computationally designed peptide macrocycle inhibitors of New Delhi metallo-β-lactamase 1
Mulligan, V. K., Workman, S. D., Sun, T., Rettie, S., Li, X., Worrall, L. J., Craven, T. W., King, D. T., Hosseinzadeh, P., Watkins, A. M., et al. (2021) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.2012800118 · Cited by 87
“The current drug discovery process has shown exponentially decaying efficiency over the past several decades in terms of new drugs found per research dollar invested (9).”
Silva, T. C., Eppink, M. H. M., & Ottens, M. (2021) · Journal of Chemical Technology & Biotechnology · doi:10.1002/jctb.6792 · Cited by 86
Hadar, N., Raman, G., Moorthy, D., O’Donnell, T. F. X., Thaler, D. E., Feldmann, E. G., Lau, J., Kitsios, G. D., & Dahabreh, I. J. (2014) · Cerebrovascular Diseases · doi:10.1159/000365206 · Cited by 80
Ye, F. (2014) · Frontiers in Pharmacology · doi:10.3389/fphar.2014.00052 · Cited by 83
Jackson, N., Atar, D., Borentain, M., Breithardt, G., van Eickels, M., Endres, M., Fraass, U., Friede, T., Hannachi, H., Janmohamed, S., et al. (2016) · European Heart Journal · doi:10.1093/eurheartj/ehv213 · Cited by 76
Nijsen, M., Wu, F., Bansal, L., Bradshaw‐Pierce, E. L., Chan, J. R., Liederer, B. M., Mettetal, J. T., Schroeder, P. E., Schuck, E. L., Tsai, A., et al. (2018) · CPT Pharmacometrics & Systems Pharmacology · doi:10.1002/psp4.12282 · Cited by 80
“8 billion per newly approved drug(1)); a problem that is not new to the pharmaceutical industry as other reports show a decline in the number of new drug approvals per dollar spent over the last decades.(2) Approximately 90% of investigational drugs fail before being approved for use in patients, mostly attributed to…”
BackgroundCreating Patient-Specific Neural Cells for the In Vitro Study of Brain Disorders
Brennand, K. J., Marchetto, M. C., Benvenisty, N., Brüstle, O., Ebert, A., Izpisua Belmonte, J. C., Kaykas, A., Lancaster, M. A., Livesey, F. J., McConnell, M. J., et al. (2015) · Stem Cell Reports · doi:10.1016/j.stemcr.2015.10.011 · Cited by 77
“This represents a significant improvement of previous experimental tools, including animal models and in vitro cultures of non-relevant cell lines (such as 293T or HeLa cells), which recapitulate only some of the specific traits of human disease (Eglen and Reisine, 2011; Pouton and Haynes, 2005), with the potential to…”
Multiobjective de novo drug design with recurrent neural networks and nondominated sorting
Yasonik, J. (2020) · Journal of Cheminformatics · doi:10.1186/s13321-020-00419-6 · Cited by 90
Shen, M., Quertermous, T., Fischbein, M. P., & Wu, J. C. (2021) · Circulation Research · doi:10.1161/circresaha.120.318049 · Cited by 80
Arzi, R. S., & Sosnik, A. (2018) · Advanced Drug Delivery Reviews · doi:10.1016/j.addr.2018.07.012 · Cited by 81
The endless frontier? The recent increase of R&D productivity in pharmaceuticals
Pammolli, F., Righetto, L., Abrignani, S., Pani, L., Pelicci, P. G., & Rabosio, E. (2020) · Journal of Translational Medicine · doi:10.1186/s12967-020-02313-z · Cited by 77
Synthetic cells in biomedical applications
Sato, W., Zajkowski, T., Moser, F., & Adamala, K. P. (2021) · Wiley Interdisciplinary Reviews Nanomedicine and Nanobiotechnology · doi:10.1002/wnan.1761 · Cited by 85
Wang, X., Cheng, Y., Yang, Y., Yu, Y., Li, F., & Peng, S. (2023) · Nature Machine Intelligence · doi:10.1038/s42256-023-00640-6 · Cited by 84
“We can draw two important findings on the basis of the experiment results: (1) the combinations of multimodal SSL tasks achieve a state-of-the-art drug discovery performance; (2) the joint training of local and global SSL tasks is superior to the random combinations of two SSL tasks when there are the same number of m…”
InfluentialPrediction of disease–gene–drug relationships following a differential network analysis
Zickenrott, S., Angarica, V. E., Upadhyaya, B. B., & del Sol, A. (2016) · Cell Death and Disease · doi:10.1038/cddis.2015.393 · Cited by 86
“7,8 In the past years, the large-scale generation of high-throughput biological data has enabled the construction of complex interaction networks that provide a new framework for gaining a systems level understanding of disease mechanisms.”
BackgroundIntroduction to the EQIPD quality system
Bespalov, A., Bernard, R., Gilis, A., Gerlach, B., Guillén, J., Castagné, V., Lefevre, I. A., Ducrey, F., Monk, L., Bongiovanni, S., et al. (2021) · eLife · doi:10.7554/elife.63294 · Cited by 76
Machine Learning guided early drug discovery of small molecules
Pillai, N., Dasgupta, A., Sudsakorn, S., Fretland, J., & Mavroudis, P. D. (2022) · Drug Discovery Today · doi:10.1016/j.drudis.2022.03.017 · Cited by 85
Bioactive natural derivatives of phthalate ester
Roy, R. N. (2020) · Critical Reviews in Biotechnology · doi:10.1080/07388551.2020.1789838 · Cited by 75
Carter-Fenk, K., Lao, K. U., & Herbert, J. M. (2021) · Accounts of Chemical Research · doi:10.1021/acs.accounts.1c00387 · Cited by 75
Kumar, S. A., Kumar, T. D. A., Beeraka, N. M., Pujar, G. V., Singh, M., Akshatha, H. S., & Bhagyalalitha, M. (2021) · Future Medicinal Chemistry · doi:10.4155/fmc-2021-0243 · Cited by 95
Future technology insight: mass spectrometry imaging as a tool in drug research and development
Cobice, D., Goodwin, R. J. A., Andrén, P. E., Nilsson, A., Mackay, C. L., & Andrew, R. (2015) · British Journal of Pharmacology · doi:10.1111/bph.13135 · Cited by 75
“In recent years, significantly fewer new drugs have been licensed, with escalating costs of research and development (Scannell et al., 2012).”
BackgroundApplication of Metabolomics to Quality Control of Natural Product Derived Medicines
Lee, K., Jeon, J.-Y., Lee, B.-J., Lee, H., & Choi, H. (2017) · Biomolecules & Therapeutics · doi:10.4062/biomolther.2016.249 · Cited by 83
“Recently, the process of drug discovery and development has become very expensive while simultaneously, the number of new drug approvals is steadily declining (Scannell et al., 2012).”
BackgroundEnhancing the Promise of Drug Repositioning through Genetics
Pritchard, J.-L., O’Mara, T. A., & Glubb, D. M. (2017) · Frontiers in Pharmacology · doi:10.3389/fphar.2017.00896 · Cited by 80
Immuno-psychiatry: an agenda for clinical practice and innovative research
Leboyer, M., Berk, M., Yolken, R. H., Tamouza, R., Kupfer, D. J., & Groc, L. (2016) · BMC Medicine · doi:10.1186/s12916-016-0712-5 · Cited by 76
“Despite major advances in the understanding of severe psychiatric disorders, the number of new drugs made available is steadily declining [53].”
BackgroundStadler, M., Walter, S., Walzl, A., Kramer, N., Unger, C., Scherzer, M., Unterleuthner, D., Hengstschläger, M., Krupitza, G., & Dolznig, H. (2015) · Seminars in Cancer Biology · doi:10.1016/j.semcancer.2015.08.007 · Cited by 82
Strategic Patenting by Pharmaceutical Companies – Should Competition Law Intervene?
Gurgula, O. (2020) · IIC - International Review of Intellectual Property and Competition Law · doi:10.1007/s40319-020-00985-0 · Cited by 98
“4 Pammolli et al. (2011); Scannell et al. (2012); Light and Lexchin (2012).”
Recent Developments on Ionic Liquids and Deep Eutectic Solvents for Drug Delivery Applications
Qader, I. B., & Prasad, K. (2022) · Pharmaceutical Research · doi:10.1007/s11095-022-03315-w · Cited by 79
Innovation in oncology clinical trial design
Verweij, J., Hendriks, H. R., Zwierzina, H., Hanauske, Wacheck, V., Collignon, O., Bruzzi, P., Gross, J., Riehl, T., Bretz, F., et al. (2019) · Cancer Treatment Reviews · doi:10.1016/j.ctrv.2019.01.001 · Cited by 78
Mind and machine in drug design
Schneider, G. (2019) · Nature Machine Intelligence · doi:10.1038/s42256-019-0030-7 · Cited by 73
The researchers’ view of scientific rigor—survey on the conduct and reporting of in vivo research
Reichlin, T. S., Vogt, L., & Würbel, H. (2016) · PLOS ONE · doi:10.1371/journal.pone.0165999 · Cited by 72
“It also increases R&D costs in drug development [22], resulting in higher health care costs (e.”
BackgroundSharma, I., & Tan, D. S. (2013) · Nature Chemistry · doi:10.1038/nchem.1581 · Cited by 72
Leil, T. A., & Bertz, R. (2014) · Frontiers in Pharmacology · doi:10.3389/fphar.2014.00247 · Cited by 80
“…difficulty in finding novel therapeutic targets, either for diseases with well established standards of care or those with unmet medical need (Pammolli et al., 2011; Scannell et al., 2012), and the other being the increasing cost associated with discovery and drug development of new drugs.”
BackgroundDeveloping New Immunosuppression for the Next Generation of Transplant Recipients: The Path Forward
Stegall, M. D., Morris, R. E., Alloway, R. R., & Mannon, R. B. (2016) · American Journal of Transplantation · doi:10.1111/ajt.13582 · Cited by 73
Evolutionary prediction of medicinal properties in the genus Euphorbia L.
Ernst, M., Saslis-Lagoudakis, C., Grace, O., Nilsson, N., Simonsen, H. T., Horn, J. W., & Rønsted, N. (2016) · Scientific Reports · doi:10.1038/srep30531 · Cited by 65
“…cost-intensive work with naturally derived chemicals, fear of duplication, intellectual property concerns or biodiversity conservation issues 46–48 plant-derived drugs continue to be part of the list of essential medicines for priority diseases published by the WHO (WHO Model List of Essential…”
3D cell culture models and organ‐on‐a‐chip: Meet separation science and mass spectrometry
Lin, A., Skottvoll, F. S., Rayner, S., Pedersen‐Bjergaard, S., Sullivan, G. J., Krauss, S. J. K., Wilson, S. R., & Harrison, S. P. (2019) · Electrophoresis · doi:10.1002/elps.201900170 · Cited by 76
Molecular modelling of mebendazole polymorphs as a potential colchicine binding site inhibitor
Al-Karmalawy, A. A., & Khattab, M. (2020) · New Journal of Chemistry · doi:10.1039/d0nj02844d · Cited by 75
Evolving Paradigms of Recombinant Protein Production in Pharmaceutical Industry: A Rigorous Review
Jayakrishnan, A., Rosli, W. R. W., Tahir, A. R. M., Razak, F. S. A., Kee, P. E., Ng, H. S., Chew, Y.-L., Lee, S.-K., Ramasamy, M., Tan, C. S., et al. (2024) · Sci · doi:10.3390/sci6010009 · Cited by 84
“However, a closer look at the problems ailing the industry for the past few decades will shed light on its declining productivity within the R&D division, thereby leading to increased product costs [88].”
BackgroundPrioritizing multiple therapeutic targets in parallel using automated DNA-encoded library screening
Machutta, C. A., Kollmann, C. S., Lind, K. E., Bai, X., Chan, P. F., Huang, J., Ballell, L., Belyanskaya, S. L., Besra, G. S., Barros-Aguirre, D., et al. (2017) · Nature Communications · doi:10.1038/ncomms16081 · Cited by 70
Lessons from Toxicology: Developing a 21st-Century Paradigm for Medical Research
Langley, G., Austin, C. P., Balapure, A. K., Birnbaum, L. S., Bucher, J. R., helen, F. J., Fitzpatrick, S. C., Fowle, J. R., Kavlock, R. J., Kitano, H., et al. (2015) · Environmental Health Perspectives · doi:10.1289/ehp.1510345 · Cited by 74
“This understanding is a vital need, in view of current failures (Scannell et al. 2012; Kaitin and DiMasi 2011) in health research, drug discovery, and clinical transla tion (Collins 2011).”
Using Big Data to Discover Diagnostics and Therapeutics for Gastrointestinal and Liver Diseases
Wooden, B., Goossens, N., Hoshida, Y., & Friedman, S. L. (2016) · Gastroenterology · doi:10.1053/j.gastro.2016.09.065 · Cited by 72
“activity, in order to predict the effects of a comp ound in vivo.(40,41) Phenotypic screens using animal or cell-based models of disease offer imp oved performance in this regard, but come with their own set of drawbacks, including relatively low throughput, high expense, mechanistic uncertainty, and limited cover ag…”
BackgroundIsgut, M., Mukkavilli, R., Yang, C., Subrahmanyam, V., Rida, P. C. G., & Aneja, R. (2017) · Medicinal Research Reviews · doi:10.1002/med.21444 · Cited by 69
Orphan Drugs and Their Impact on Pharmaceutical Development
Attwood, M. M., Rask‐Andersen, M., & Schiöth, H. B. (2018) · Trends in Pharmacological Sciences · doi:10.1016/j.tips.2018.03.003 · Cited by 69
Douglass, E. F., Allaway, R. J., Szalai, B., Wang, W., Tian, T., Fernández-Torras, A., Realubit, R., Karan, C., Zheng, S., Pessia, A., et al. (2022) · Cell Reports Medicine · doi:10.1016/j.xcrm.2021.100492 · Cited by 68
Active learning framework leveraging transcriptomics identifies modulators of disease phenotypes
DeMeo, B., Nesbitt, C., Miller, S. A., Burkhardt, D. B., Lipchina, I., Fu, D., Holderrieth, P., Kim, D., Kolchenko, S., Szałata, A., et al. (2025) · Science · doi:10.1126/science.adi8577 · Cited by 86
“…a molecular signature of the disease process ( 15 ), can enhance clinical translation but have lower through-put and greater cost; conversely, simpler phenotypic measurement and model combinations support cost-effective, high-throughput screens but have reduced clinical translatability ( 5 , 16 ).”
Creating cell and animal models of human disease by genome editing using CRISPR/Cas9
Zarei, A., Razban, V., Hosseini, S. E., & Tabei, K. (2019) · The Journal of Gene Medicine · doi:10.1002/jgm.3082 · Cited by 74
Current Challenges and Opportunities in Designing Protein–Protein Interaction Targeted Drugs
Shin, W., Kumazawa, K., Imai, K., Hirokawa, T., & Kihara, D. (2020) · Advances and Applications in Bioinformatics and Chemistry · doi:10.2147/aabc.s235542 · Cited by 100
Recent applications of quantitative systems pharmacology and machine learning models across diseases
Aghamiri, S. S., Amin, R., & Helikar, T. (2021) · Journal of Pharmacokinetics and Pharmacodynamics · doi:10.1007/s10928-021-09790-9 · Cited by 71
Industrielle Anwendungen der Diels‐Alder‐Reaktion
Funel, J., & Abele, S. (2013) · Angewandte Chemie · doi:10.1002/ange.201201636 · Cited by 67
Big biomedical data and cardiovascular disease research: opportunities and challenges
Denaxas, S., & Morley, K. I. (2015) · European Heart Journal - Quality of Care and Clinical Outcomes · doi:10.1093/ehjqcco/qcv005 · Cited by 72
Anthelmintics for drug repurposing: Opportunities and challenges
Alavi, S. E., & Shahmabadi, H. E. (2021) · Saudi Pharmaceutical Journal · doi:10.1016/j.jsps.2021.04.004 · Cited by 69
CANDO and the infinite drug discovery frontier
Minie, M., Chopra, G., Sethi, G., Horst, J. A., White, G. W. N., Roy, A., Hatti, K. S., & Samudrala, R. (2014) · Drug Discovery Today · doi:10.1016/j.drudis.2014.06.018 · Cited by 69
Racing to define pharmaceutical R&D external innovation models
Wang, L., Plump, A. S., & Ringel, M. S. (2014) · Drug Discovery Today · doi:10.1016/j.drudis.2014.10.008 · Cited by 67
Developability assessment as an early de-risking tool for biopharmaceutical development
Zurdo, J. (2013) · Pharmaceutical Bioprocessing · doi:10.4155/pbp.13.3 · Cited by 75
Dexpramipexole as an oral steroid-sparing agent in hypereosinophilic syndromes
Panch, S. R., Bozik, M. E., Brown, T., Makiya, M. A., Prussin, C., Archibald, D., Hebrank, G. T., Sullivan, M. E., Sun, X., Wetzler, L., et al. (2018) · Blood · doi:10.1182/blood-2018-02-835330 · Cited by 66
Analysis of energy-related CO2 emissions in China's pharmaceutical industry and its driving forces
Gao, Z., Geng, Y., Wu, R., Chen, W., Wu, F., & Tian, X. (2019) · Journal of Cleaner Production · doi:10.1016/j.jclepro.2019.03.092 · Cited by 69
Key indicators of phase transition for clinical trials through machine learning
Feijoo, F., Palopoli, M., Bernstein, J., Siddiqui, S., & Albright, T. E. (2020) · Drug Discovery Today · doi:10.1016/j.drudis.2019.12.014 · Cited by 58
DeepDelta: predicting ADMET improvements of molecular derivatives with deep learning
Fralish, Z., Chen, A., Skaluba, P., & Reker, D. (2023) · Journal of Cheminformatics · doi:10.1186/s13321-023-00769-x · Cited by 66
“Unfortunately, such characterizations are laborious and expensive and can include complex in vivo experiments [2].”
BackgroundCichońska, A., Rousu, J., & Aittokallio, T. A. (2015) · Expert Opinion on Drug Discovery · doi:10.1517/17460441.2015.1096926 · Cited by 71
“However, despite the continuous increase in the number of promising therapeutic targets, the amount of new drugs approved by US FDA per billion dollars (inflation-adjusted) spent on R&D has halved every 9 years since 1950 [1].”
BackgroundInvestigation and assessment of blockchain technology adoption in the pharmaceutical supply chain
Badhotiya, G. K., Sharma, V. P., Prakash, S., Vinayak, K., & Singh, R. (2021) · Materials Today Proceedings · doi:10.1016/j.matpr.2021.01.673 · Cited by 66
Clinical research framework proposal for ketogenic metabolic therapy in glioblastoma
Duraj, T., Kalamian, M., Zuccoli, G., Maroon, J. C., D’Agostino, D. P., Scheck, A. C., Poff, A. M., Winter, S. F., Hu, J. L., Klement, R. J., et al. (2024) · BMC Medicine · doi:10.1186/s12916-024-03775-4 · Cited by 72
Significance and future role of microbial resource centers
Overmann, J. (2015) · Systematic and Applied Microbiology · doi:10.1016/j.syapm.2015.02.008 · Cited by 64
The NCATS Pharmaceutical Collection: a 10-year update
Huang, R., Zhu, H., Shinn, P., Ngan, D. K., Ye, L., Thakur, A., Grewal, G. S., Zhao, T., Southall, N. T., Hall, M. D., et al. (2019) · Drug Discovery Today · doi:10.1016/j.drudis.2019.09.019 · Cited by 64
Re-energizing the Development of Pain Therapeutics in Light of the Opioid Epidemic
Skolnick, P., & Volkow, N. D. (2016) · Neuron · doi:10.1016/j.neuron.2016.09.051 · Cited by 63
“The combination of a medication (or in this instance, a class of medications) with high efficacy and relatively low cost has been termed the ‘‘better than the Beatles’’ phenomenon (Scannell et al., 2012) and presents a strong disincentive to develop alternatives for the treatment of acute pain.”
BackgroundMeco, D., Attinà, G., Mastrangelo, S., Navarra, P., & Ruggiero, A. (2023) · International Journal of Molecular Sciences · doi:10.3390/ijms24021334 · Cited by 72
“In recent years, the pool of newly discovered and Food and Drug Administration (FDA)-approved drugs has diminished [6], primarily due to the increasing cost of clinical trials [7].”
BackgroundImpact of preformulation on drug development
Bharate, S. S., & Vishwakarma, R. A. (2013) · Expert Opinion on Drug Delivery · doi:10.1517/17425247.2013.783563 · Cited by 82
“Prediction of potency at target, potency at likely toxicity sites, potency in cellular assays and prediction of ADMET at early stages of drug discovery research is now gaining importance [120,121].”
BackgroundBiomarkers in Pharmaceutical Research
Zhao, X., Modur, V., Carayannopoulos, L. N., & Laterza, O. (2015) · Clinical Chemistry · doi:10.1373/clinchem.2014.231712 · Cited by 77
Davis, E., Sloan, T. J., Aurelius, K., Barbour, A., Bodey, E., Clark, B., Dennis, C., Drown, R. M., Fleming, M., Humbert, A., et al. (2017) · MicrobiologyOpen · doi:10.1002/mbo3.435 · Cited by 68
Reflections on the Future of Pharmaceutical Public-Private Partnerships: From Input to Impact
de Vrueh, R. L. A., & Crommelin, D. J. A. (2017) · Pharmaceutical Research · doi:10.1007/s11095-017-2192-5 · Cited by 63
“In fact, the rate of development by pharmaceutical companies of innovative medicinal products which were approved by regulatory authorities slowed down (8,9), indicating that a number of chasms continue to exist in the translational process.”
BackgroundThe paradox of sustainable innovation: The ‘Eroom’ effect (Moore’s law backwards)
Hall, J. K., Matos, S. V., Gold, S., & Severino, L. S. (2017) · Journal of Cleaner Production · doi:10.1016/j.jclepro.2017.07.162 · Cited by 70
“The problem is progressive and intractable” (Scannell et al., 2012, p 193).”
BackgroundInfluentialMizoguchi, R., Waraya, H., & Hirakura, Y. (2019) · Molecular Pharmaceutics · doi:10.1021/acs.molpharmaceut.9b00105 · Cited by 63
Computational Drug Repositioning: Current Progress and Challenges
Ko, Y. (2020) · Applied Sciences · doi:10.3390/app10155076 · Cited by 67
“In fact, it takes about 14 years to develop new drugs through de novo drug discovery [1] (Figure 1).”
Background
Metadata
- Authors
- Scannell, J. W., Blanckley, A., Boldon, H., & Warrington, B.
- Corresponding author
- Scannell, Jack W.
- ORCID
- Scannell, Jack W.
- Venue
- Nature Reviews Drug Discovery
- Published
- 2012-03
- Volume
- 11
- Issue
- 3
- Pages
- 191-200
- ISSN
- 1474-1776 (ISSN-L)
- 1474-1784
- OpenAlex
- W2028279608
- Cited by
- 1,981
- References
- 85
- Citations by year
- 2026: 135 · 2025: 123 · 2024: 144 · 2023: 126 · 2022: 141 · 2021: 173 · 2020: 178 · 2019: 144 · 2018: 138 · 2017: 133 · 2016: 155 · 2015: 136 · 2014: 108 · 2013: 103 · 2012: 41
- FWCI
- 47.94
- Type
- journal article
- Language
- en
- Open access
- closed
- Licence
- www.springer.com/tdm (tdm)
- Locations
- Nature Reviews Drug Discovery (publishedVersion)
- PubMed (publishedVersion)
- Topics
- Social Sciences › Economics, Econometrics and Finance › Economics and Econometrics › Pharmaceutical Economics and Policy
- Health Sciences › Medicine › Public Health, Environmental and Occupational Health › Health and Medical Research Impacts
- Health Sciences › Nursing › Issues, ethics and legal aspects › Pharmaceutical industry and healthcare
- Keywords
- new drug approvals, drug approval rates, drug development costs, regulatory policy, drug regulation, basic research
- MeSH terms
- Animals, Drug Industry, Pharmaceutical Preparations, Humans, Research, Drug Delivery Systems, Efficiency, Organizational
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.